Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 1 |
2012 | 1 |
2024 | 0 |
PubMed for id: 200018496
2 results
Results by year
Filters applied: . Clear all
Page 1
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3.
Mol Cancer Ther. 2012.
PMID: 22761403
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ.
Finn RS, et al.
Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.
Breast Cancer Res. 2009.
PMID: 19874578
Free PMC article.
Item in Clipboard
Cite
Cite